Did the study find GLP-1 drugs cause preterm birth?

No. Raised risk appeared only where the medicines were used for diabetes, not for weight management — pointing to the underlying condition rather than the drug.

Why does the indication split matter so much?

A drug effect should not depend on why the drug was prescribed. That it did is evidence the association tracks the diabetes.

What are the study's limits?

It is observational, residual confounding within groups remains possible, and it reports obstetric outcomes rather than longer-term outcomes for children.

Research & Regulatory News

A Nationwide Cohort, and a Result That Points Away From the Drug

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Hviid and colleagues examined periconceptional GLP-1 receptor agonist exposure and obstetric outcomes across Danish health registries from October 2009 to December 2023, published in Human Reproduction Open in 2026. Preterm birth risk was raised where the medicines were used for diabetes but not for weight management.

Key facts

Study: Hviid 2026 (PMID 41852577)
Journal: Hum Reprod Open
Design: Nationwide observational cohort
Data source: Danish health registries
Period: October 2009 – December 2023
Liraglutide, diabetes: Preterm birth aOR 1.70 (1.17–2.48)
Semaglutide, diabetes: Preterm birth aOR 1.84 (1.24–2.7)
Weight management: Association not seen

Why Danish registries suit this question

They link prescribing, diagnoses and outcomes across an entire population with very little loss to follow-up. Pregnancy outcomes in people exposed to a specific medicine around conception is a question requiring both completeness and scale, and no trial would ever be conducted to answer it — exposure in pregnancy is not something anyone randomises.

What was found

Increased preterm birth risk among those using the medicines for diabetes: liraglutide adjusted odds ratio 1.70 with a 95% confidence interval of 1.17 to 2.48, and semaglutide 1.84 with an interval of 1.24 to 2.7. Among those using them for weight management, the association was not present.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why the split is the actual result

Same medicines, same registry, same outcome, same period. The distinguishing feature between the two groups is the condition that prompted prescribing. A drug effect should not depend on why the drug was given, so the pattern points to the underlying diabetes rather than the medication — which the authors state as their own interpretation.

Why diabetes is a plausible cause here

Diabetes in pregnancy is an established risk factor for preterm birth through mechanisms long documented and independent of any modern medicine. An association appearing only where diabetes is present is consistent with the condition doing what it has always been known to do.

What the background section establishes about scale

The paper notes these agents are rapidly expanding among reproductive-age women, that they are not approved for use in pregnancy, and that inadvertent periconceptional exposure occurs frequently. It also notes that small studies have suggested no increased risk of major congenital malformations while comprehensive obstetric outcome data remained lacking — which is the gap this study addresses.

The limits

It is observational. Confounding by indication is what the design illuminates rather than something it wholly escapes, and residual confounding within each indication group remains possible. It reports obstetric outcomes rather than long-term outcomes for children, which is a separate question requiring longer follow-up.

The boundary

These are licensed medicines, not approved for use in pregnancy, prescribed and monitored clinically. Nothing supplied on this site is any of them, and nothing here is advice. Reproductive decisions belong with a clinician.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Did the study find GLP-1 drugs cause preterm birth?: No. Raised risk appeared only where the medicines were used for diabetes, not for weight management — pointing to the underlying condition rather than the drug.
Why does the indication split matter so much?: A drug effect should not depend on why the drug was prescribed. That it did is evidence the association tracks the diabetes.
What are the study's limits?: It is observational, residual confounding within groups remains possible, and it reports obstetric outcomes rather than longer-term outcomes for children.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum